EIP
PCRX icon

Epoch Investment Partners’s Pacira BioSciences PCRX Stock Holding History

Epoch Investment Partners’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-701,585
Closed -$21.9M – 326
2018
Q1 		$21.9M Buy
701,585
+33,198
+5% +$1.18M 0.08% 176
2017
Q4 		$30.5M Buy
668,387
+132,388
+25% +$5.25M 0.1% 153
2017
Q3 		$20.1M Buy
535,999
+354,728
+196% +$14.3M 0.07% 186
2017
Q2 		$8.65M Buy
181,271
+11,988
+7% +$556K 0.03% 233
2017
Q1 		$7.72M Buy
+169,283
New +$7.32M 0.03% 231

Other funds holding PCRX

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
ECP
Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return

Epoch Investment Partners's PCRX Position: Q2 2018 in Review

Epoch Investment Partners sold out of Pacira BioSciences (PCRX) in Q2 2018, closing a stake of 701,585 shares — an estimated $21.9M sold.

Epoch Investment Partners first reported a position in PCRX in Q1 2017 and held it in 5 quarters. The position peaked at $30.5M in Q4 2017. 156 funds tracked by Wall St. Rank hold PCRX as of Q2 2018.

  • Epoch Investment Partners reported no remaining Pacira BioSciences position as of Q2 2018 after selling out during the quarter.
  • Epoch Investment Partners sold 701,585 Pacira BioSciences shares in Q2 2018, an estimated $21.9M.
  • Epoch Investment Partners first reported a position in Pacira BioSciences in Q1 2017 and held it in 5 quarters.
  • Epoch Investment Partners's Pacira BioSciences position peaked at $30.5M in Q4 2017.
  • 156 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2018.

Based on Epoch Investment Partners's 13F filing for Q2 2018, filed 13 Aug 2018.